Takeda's plaque psoriasis pill beats Sotyktu Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 11 June, 2026

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

presented by De­liv­er­ing ex­cel­lence, close to home: Build­ing the in­fra­struc­ture for mod­ern com­mu­ni­ty on­col­o­gy

Spotlight Biopharma’s golden parachutes: 12 execs who took in the biggest M&A windfalls of $35M+ Endpoints Women in Biopharma: Nominate for 2026

news Exclusive: Genentech lays off top scientist Vishva Dixit, closes infectious disease research unit in restructuring Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3 Neion Bio lands $23M Series A to make proteins from chicken eggs

The global one-stop conference convening experts across the drug discovery and development pipeline that will reshape the future of oncology therapeutics. sponsored by American Association for Cancer Research

PHARMA 'Going for our own moonshot': Parabilis CEO on biotech's record IPO •  Parabilis' $670M IPO sets new biotech record, will fund cancer drug Now at FDA’s doorstep, Beren Therapeutics tacks on $300M in new financings

Research Assistant (Chemistry) Arnatar San Diego, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. SonoThera raises $125M for non-viral gene therapy approach 2. Novartis and Orionis strike second molecular glue deal for $40M upfront 3. Ethyreal lands $101M to treat both Graves' and thyroid eye disease 4. Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study 5. News Briefing Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem Foundation 6. Pfizer CEO warns German investment at risk over drug pricing policies 7. Diabetes conference expulsions lead to apology and resignations